{
      "Rank": 17,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [],
      "ArmGroupInterventionName": [],
      "ArmGroupLabel": [],
      "ArmGroupType": [],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04456439"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19."
      ],
      "BriefTitle": [
            "Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)"
      ],
      "CentralContactEMail": [
            "elizabeth.burke@mesoblast.com",
            "ken.borow@mesoblast.com"
      ],
      "CentralContactName": [
            "Elizabeth Burke, ANP-C",
            "Kenneth M. Borow, MD"
      ],
      "CentralContactPhone": [
            "646-315-1725",
            "610-299-7855"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [],
      "CompletionDateType": [],
      "Condition": [
            "Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)"
      ],
      "ConditionAncestorId": [
            "D000004194",
            "D000010335",
            "D000012141",
            "D000007239",
            "D000011024",
            "D000011014",
            "D000014777",
            "D000003333",
            "D000030341",
            "D000012327",
            "D000008171",
            "D000012140"
      ],
      "ConditionAncestorTerm": [
            "Disease",
            "Pathologic Processes",
            "Respiratory Tract Infections",
            "Infections",
            "Pneumonia, Viral",
            "Pneumonia",
            "Virus Diseases",
            "Coronaviridae Infections",
            "Nidovirales Infections",
            "RNA Virus Infections",
            "Lung Diseases",
            "Respiratory Tract Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC01",
            "BC08",
            "All",
            "BC23"
      ],
      "ConditionBrowseBranchName": [
            "Infections",
            "Respiratory Tract (Lung and Bronchial) Diseases",
            "All Conditions",
            "Symptoms and General Pathology"
      ],
      "ConditionBrowseLeafAsFound": [
            "COVID-19",
            "Syndrome",
            "Coronavirus"
      ],
      "ConditionBrowseLeafId": [
            "M2562",
            "M15507",
            "M19643",
            "M9435",
            "M5520",
            "M14130",
            "M13056",
            "M13066",
            "M16674",
            "M5707",
            "M22838",
            "M14301",
            "M10320",
            "M14129"
      ],
      "ConditionBrowseLeafName": [
            "COVID-19",
            "Syndrome",
            "Coronavirus Infections",
            "Infections",
            "Communicable Diseases",
            "Respiratory Tract Infections",
            "Pneumonia",
            "Pneumonia, Viral",
            "Virus Diseases",
            "Coronaviridae Infections",
            "Nidovirales Infections",
            "RNA Virus Infections",
            "Lung Diseases",
            "Respiratory Tract Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000086382",
            "D000018352",
            "D000013577"
      ],
      "ConditionMeshTerm": [
            "COVID-19",
            "Coronavirus Infections",
            "Syndrome"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [],
      "DesignInterventionModel": [],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "This intermediate-size expanded access protocol plans to treat approximately 50 children or adolescents, male and female, with MIS-C associated with COVID-19. Participants who are 2 months to 17 years of age, inclusive, will be enrolled at multiple clinical sites across the United States."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria\n\n2 months to 17 years of age, inclusive\nPositive for current or recent SARS-CoV-2 (COVID-19) infection by real-time reverse transcription polymerase chain reaction (RT-PCR), serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms AND no alternative plausible diagnoses\n\nPresenting with:\n\nFever (>38.0\u00b0C or >100.4\u00b0F for \u226524 hours) or reporting subjective fever lasting \u226524 hours\n\nLaboratory evidence of inflammation with high sensitivity C-reactive protein (hsCRP) \u22654.0 milligrams per deciliter (mg/dL) and associated abnormalities of at least one of the following:\n\nelevated erythrocyte sedimentation rate (ESR)\nelevated fibrinogen\nelevated procalcitonin\nelevated d-dimer\nelevated ferritin\nelevated lactic dehydrogenase (LDH)\nelevated interleukin 6 (IL-6)\nelevated neutrophils\nreduced lymphocytes\nlow albumin\n\nClinically severe multisystem illness requiring hospitalization with evidence for cardiac involvement plus at least one other organ involvement (renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological)\n\nCardiac involvement is defined as reduced left ventricular ejection fraction (<55%) in addition to at least one of the following:\n\nincreased troponin I,\nincreased N-terminal pro-B-type natriuretic peptide (NT-proBNP) or BNP and/or\nechocardiographic and/or other imaging evidence of left anterior descending coronary artery (LAD) and/or right coronary artery (RCA) dilation associated with a z-score > 2.5\nIf on mechanical ventilation or ECMO, \u226472 hours post initiation of the respiratory support device\n\nExclusion Criteria\n\nDocumented other microbial cause for MIS-C including bacterial sepsis, staphylococcal or streptococcal shock syndromes, or infections associated with myocarditis such as enterovirus. Of importance, waiting for results of these investigations should not delay initiation of remestemcel-L therapy.\nFemales who are pregnant or lactating\nBody mass index (BMI) \u226540 kilograms per square meter (kg/m^2)\nKnown hypersensitivity to dimethyl sulfoxide (DMSO) or to porcine or bovine proteins\nAspartate aminotransferase/alanine transaminase (AST/ALT) \u22655x upper limit of normal (ULN)\nCreatinine clearance <30 mL/min\nSerum creatinine >2 mg/dL\nAny end-stage organ disease which in the opinion of the treating physician may possibly affect the safety of the remestemcel-L treatment."
      ],
      "EnrollmentCount": [],
      "EnrollmentType": [],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [
            "Yes"
      ],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000893",
            "D000068776",
            "D000006993",
            "D000002492",
            "D000045505",
            "D000000779",
            "D000000777",
            "D000018689",
            "D000018373",
            "D000000932",
            "D000001337",
            "D000005765",
            "D000006634",
            "D000006633",
            "D000018494",
            "D000018377",
            "D000045504",
            "D000018926",
            "D000000982",
            "D000003879",
            "D000000998",
            "D000000890"
      ],
      "InterventionAncestorTerm": [
            "Anti-Inflammatory Agents",
            "Sleep Aids, Pharmaceutical",
            "Hypnotics and Sedatives",
            "Central Nervous System Depressants",
            "Physiological Effects of Drugs",
            "Anesthetics, Local",
            "Anesthetics",
            "Sensory System Agents",
            "Peripheral Nervous System Agents",
            "Antiemetics",
            "Autonomic Agents",
            "Gastrointestinal Agents",
            "Histamine H1 Antagonists",
            "Histamine Antagonists",
            "Histamine Agents",
            "Neurotransmitter Agents",
            "Molecular Mechanisms of Pharmacological Action",
            "Anti-Allergic Agents",
            "Antipruritics",
            "Dermatologic Agents",
            "Antiviral Agents",
            "Anti-Infective Agents"
      ],
      "InterventionArmGroupLabel": [],
      "InterventionBrowseBranchAbbrev": [
            "Infl",
            "All",
            "AAll",
            "AnEm",
            "CNSDep",
            "Gast",
            "Derm",
            "Infe"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Inflammatory Agents",
            "All Drugs and Chemicals",
            "Anti-Allergic Agents",
            "Antiemetics",
            "Central Nervous System Depressants",
            "Gastrointestinal Agents",
            "Dermatologic Agents",
            "Anti-Infective Agents"
      ],
      "InterventionBrowseLeafAsFound": [
            "Pump",
            "Rivaroxaban",
            "Rivaroxaban",
            "1440"
      ],
      "InterventionBrowseLeafId": [
            "M9064",
            "M155022",
            "M228602",
            "M263157",
            "M6490",
            "M13420",
            "M186752",
            "M3369",
            "M9195",
            "M3259",
            "M3261",
            "M3403",
            "M8033",
            "M8862",
            "M8860",
            "M212140",
            "M8861",
            "M19657",
            "M20115",
            "M6226",
            "M3466",
            "M3366"
      ],
      "InterventionBrowseLeafName": [
            "Hydrocortisone",
            "Hydrocortisone 17-butyrate 21-propionate",
            "Hydrocortisone acetate",
            "Hydrocortisone hemisuccinate",
            "Diphenhydramine",
            "Promethazine",
            "Remestemcel-l",
            "Anti-Inflammatory Agents",
            "Hypnotics and Sedatives",
            "Anesthetics",
            "Anesthetics, Local",
            "Antiemetics",
            "Gastrointestinal Agents",
            "Histamine H1 Antagonists",
            "Histamine",
            "Histamine phosphate",
            "Histamine Antagonists",
            "Neurotransmitter Agents",
            "Anti-Allergic Agents",
            "Dermatologic Agents",
            "Antiviral Agents",
            "Anti-Infective Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Participants may receive up to 2 infusions of 2 x 10^6 remestemcel-L within a 5-day period.",
            "Participants who are not currently taking a corticosteroid will receive hydrocortisone, 0.5-1 milligram per kilogram (mg/kg), up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.",
            "Participants will receive diphenhydramine, 0.5-1 mg/kg, up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L."
      ],
      "InterventionMeshId": [
            "D000004155",
            "D000011398",
            "C000711674",
            "D000006854"
      ],
      "InterventionMeshTerm": [
            "Diphenhydramine",
            "Promethazine",
            "Remestemcel-l",
            "Hydrocortisone"
      ],
      "InterventionName": [
            "Remestemcel-L",
            "Hydrocortisone",
            "Diphenhydramine"
      ],
      "InterventionOtherName": [
            "Benadryl\u00ae"
      ],
      "InterventionType": [
            "Biological",
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "MIS-C",
            "COVID-19",
            "MSC",
            "remestemcel-L",
            "Mesoblast",
            "mesenchymal",
            "cellular therapy",
            "cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "April 20, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "April 12, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Mesoblast International S\u00e0rl"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [],
      "LocationFacility": [],
      "LocationState": [],
      "LocationStatus": [],
      "LocationZip": [],
      "MaximumAge": [
            "17 Years"
      ],
      "MinimumAge": [
            "2 Months"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Mesoblast, Ltd."
      ],
      "OrgStudyId": [
            "MSB-MSC-MISC001"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Mesoblast, Inc."
      ],
      "OverallOfficialName": [
            "Kenneth M. Borow, MD"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Available"
      ],
      "OversightHasDMC": [],
      "PatientRegistry": [],
      "Phase": [],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [],
      "PrimaryCompletionDateType": [],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [],
      "PrimaryOutcomeTimeFrame": [],
      "ReferenceCitation": [
            "Eckard AR, Borow KM, Mack EH, Burke E, Atz AM. Remestemcel-L Therapy for COVID-19-Associated Multisystem Inflammatory Syndrome in Children. Pediatrics. 2021 May;147(5). pii: e2020046573. doi: 10.1542/peds.2020-046573. Epub 2021 Feb 12."
      ],
      "ReferencePMID": [
            "33579813"
      ],
      "ReferenceType": [
            "result"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [],
      "SecondaryOutcomeTimeFrame": [],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "April 2022"
      ],
      "StdAge": [
            "Child"
      ],
      "StudyFirstPostDate": [
            "July 2, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "June 29, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "June 30, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Expanded Access"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": []
}